FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2596490427> ?p ?o ?g. }

• W2596490427 endingPage "4126" @default.
• W2596490427 startingPage "4119" @default.
• W2596490427 abstract "Abstract Purpose: The PARP inhibitor veliparib enhances the cytotoxicity of alkylating agents. This phase I study evaluated veliparib with the bifunctional alkylator bendamustine (VB) in patients with relapsed/refractory lymphoma, multiple myeloma, and solid malignancies, with a cohort expansion of VB with rituximab (VBR) in patients with B-cell lymphomas. Experimental Design: This dose-escalation study evaluated safety, pharmacokinetics, and preliminary efficacy of veliparib (20–400 mg twice a day, days 1–7 of 28-day cycle) and bendamustine (70 and 90 mg/m2 intravenously, days 1 and 2). A cohort expansion was conducted, which combined veliparib and bendamustine at the maximum tolerated dose (MTD) with rituximab (375 mg/m2, day 1) in patients with B-cell lymphomas. Thirty-four patients were treated in seven dose-escalation cohorts and seven patients in the dose-expansion cohort. Results: The MTD was veliparib 300 mg twice daily plus bendamustine 90 mg/m2. Dose-limiting toxicities (DLT) were anemia, nausea, hypertension, and hyperhidrosis. Grade ≥3 toxicities included lymphopenia (87.8%), anemia (19.5%), neutropenia (12.2%), thrombocytopenia (9.8%), leukopenia (9.8%), nausea (7.3%), and hypophosphatemia (7.3%). Apparent veliparib clearance was slightly lower than previously reported. Of 14 patients with lymphoma evaluable for response, five of seven (71%) on VB and six of seven (86%) on VBR achieved objective response. One patient with multiple myeloma achieved partial response. Conclusions: VB and VBR were generally well-tolerated. VBR had preliminary clinical activity in patients with B-cell lymphoma, which warrants further investigation in a phase II trial. This trial was registered at www.clinicaltrials.gov as NCT01326702. Clin Cancer Res; 23(15); 4119–26. ©2017 AACR." @default.
• W2596490427 created "2017-03-23" @default.
• W2596490427 creator A5000623885 @default.
• W2596490427 creator A5001102192 @default.
• W2596490427 creator A5005037311 @default.
• W2596490427 creator A5006117950 @default.
• W2596490427 creator A5012810450 @default.
• W2596490427 creator A5013172168 @default.
• W2596490427 creator A5014543424 @default.
• W2596490427 creator A5015878509 @default.
• W2596490427 creator A5019910948 @default.
• W2596490427 creator A5027371881 @default.
• W2596490427 creator A5034595315 @default.
• W2596490427 creator A5034787589 @default.
• W2596490427 creator A5036572642 @default.
• W2596490427 creator A5045409088 @default.
• W2596490427 creator A5049461398 @default.
• W2596490427 creator A5050726526 @default.
• W2596490427 creator A5052659722 @default.
• W2596490427 creator A5061964017 @default.
• W2596490427 creator A5062879857 @default.
• W2596490427 creator A5065503391 @default.
• W2596490427 creator A5068152076 @default.
• W2596490427 creator A5068193017 @default.
• W2596490427 creator A5069406522 @default.
• W2596490427 creator A5069721801 @default.
• W2596490427 creator A5071256856 @default.
• W2596490427 creator A5072271778 @default.
• W2596490427 creator A5086473468 @default.
• W2596490427 creator A5088343926 @default.
• W2596490427 creator A5091859782 @default.
• W2596490427 date "2017-08-01" @default.
• W2596490427 modified "2023-10-16" @default.
• W2596490427 title "The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell Lymphoma" @default.
• W2596490427 cites W1751016438 @default.
• W2596490427 cites W1757805954 @default.
• W2596490427 cites W1846311518 @default.
• W2596490427 cites W1975968280 @default.
• W2596490427 cites W1980993985 @default.
• W2596490427 cites W1987087385 @default.
• W2596490427 cites W2007045175 @default.
• W2596490427 cites W2017518118 @default.
• W2596490427 cites W2018562293 @default.
• W2596490427 cites W2019607817 @default.
• W2596490427 cites W2026262714 @default.
• W2596490427 cites W2027236982 @default.
• W2596490427 cites W2038989389 @default.
• W2596490427 cites W2044436186 @default.
• W2596490427 cites W2068485245 @default.
• W2596490427 cites W2074533771 @default.
• W2596490427 cites W2077320602 @default.
• W2596490427 cites W2081040247 @default.
• W2596490427 cites W2083329993 @default.
• W2596490427 cites W2092209484 @default.
• W2596490427 cites W2116385028 @default.
• W2596490427 cites W2120755425 @default.
• W2596490427 cites W2128936398 @default.
• W2596490427 cites W2131670056 @default.
• W2596490427 cites W2131998596 @default.
• W2596490427 cites W2133201432 @default.
• W2596490427 cites W2150129319 @default.
• W2596490427 cites W2153280042 @default.
• W2596490427 cites W2164092350 @default.
• W2596490427 cites W2193278586 @default.
• W2596490427 doi "https://doi.org/10.1158/1078-0432.ccr-16-3068" @default.
• W2596490427 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5541854" @default.
• W2596490427 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28314788" @default.
• W2596490427 hasPublicationYear "2017" @default.
• W2596490427 type Work @default.
• W2596490427 sameAs 2596490427 @default.
• W2596490427 citedByCount "15" @default.
• W2596490427 countsByYear W25964904272017 @default.
• W2596490427 countsByYear W25964904272018 @default.
• W2596490427 countsByYear W25964904272019 @default.
• W2596490427 countsByYear W25964904272020 @default.
• W2596490427 countsByYear W25964904272021 @default.
• W2596490427 countsByYear W25964904272022 @default.
• W2596490427 countsByYear W25964904272023 @default.
• W2596490427 crossrefType "journal-article" @default.
• W2596490427 hasAuthorship W2596490427A5000623885 @default.
• W2596490427 hasAuthorship W2596490427A5001102192 @default.
• W2596490427 hasAuthorship W2596490427A5005037311 @default.
• W2596490427 hasAuthorship W2596490427A5006117950 @default.
• W2596490427 hasAuthorship W2596490427A5012810450 @default.
• W2596490427 hasAuthorship W2596490427A5013172168 @default.
• W2596490427 hasAuthorship W2596490427A5014543424 @default.
• W2596490427 hasAuthorship W2596490427A5015878509 @default.
• W2596490427 hasAuthorship W2596490427A5019910948 @default.
• W2596490427 hasAuthorship W2596490427A5027371881 @default.
• W2596490427 hasAuthorship W2596490427A5034595315 @default.
• W2596490427 hasAuthorship W2596490427A5034787589 @default.
• W2596490427 hasAuthorship W2596490427A5036572642 @default.
• W2596490427 hasAuthorship W2596490427A5045409088 @default.
• W2596490427 hasAuthorship W2596490427A5049461398 @default.
• W2596490427 hasAuthorship W2596490427A5050726526 @default.
• W2596490427 hasAuthorship W2596490427A5052659722 @default.
• W2596490427 hasAuthorship W2596490427A5061964017 @default.
• W2596490427 hasAuthorship W2596490427A5062879857 @default.

• next